EUCLIDS
The genetic basis of meningococcal and other life threatening bacterial infections of childhood
| Coordinatore | IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE
Organization address
address: SOUTH KENSINGTON CAMPUS EXHIBITION ROAD contact info |
| Nazionalità Coordinatore | United Kingdom [UK] |
| Totale costo | 17˙323˙678 € |
| EC contributo | 11˙988˙647 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2011-two-stage |
| Funding Scheme | CP-IP |
| Anno di inizio | 2011 |
| Periodo (anno-mese-giorno) | 2011-12-01 - 2016-11-30 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE
Organization address
address: SOUTH KENSINGTON CAMPUS EXHIBITION ROAD contact info |
UK (LONDON) | coordinator | 2˙838˙599.00 |
| 2 |
SERVIZO GALEGO DE SAUDE
Organization address
city: Santiago de Compostela contact info |
ES (Santiago de Compostela) | participant | 1˙195˙200.00 |
| 3 |
OXFORD GENE TECHNOLOGY (OPERATIONS) Ltd
Organization address
address: Begbroke Science Park, Sandy Lane, Yarnton contact info |
UK (OXFORD) | participant | 1˙092˙070.00 |
| 4 |
BIOMEDICAL SCIENCES INSTITUTES Limited by Guarantee
Organization address
address: BIOPOLIS WAY 20 contact info |
SG (SINGAPORE) | participant | 996˙000.00 |
| 5 |
Medizinische Universitaet Graz
Organization address
address: AUENBRUGGERPLATZ 2 contact info |
AT (GRAZ) | participant | 796˙800.00 |
| 6 |
Academisch Medisch Centrum bij de Universiteit van Amsterdam
Organization address
address: MEIBERGDREEF 9 contact info |
NL (AMSTERDAM) | participant | 796˙799.00 |
| 7 |
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD
Organization address
address: University Offices, Wellington Square contact info |
UK (OXFORD) | participant | 738˙802.00 |
| 8 |
MEDICAL RESEARCH COUNCIL
Organization address
address: NORTH STAR AVENUE POLARIS HOUSE contact info |
UK (SWINDON) | participant | 599˙710.00 |
| 9 |
MICROPATHOLOGY LIMITED
Organization address
address: SIR WILLIAM LYONS ROAD contact info |
UK (COVENTRY) | participant | 599˙592.00 |
| 10 |
IC CONSULTANTS LTD
Organization address
address: Sherfield Building, Imperial College of Science, Technology and Medicine contact info |
UK (LONDON) | participant | 597˙745.00 |
| 11 |
STICHTING KATHOLIEKE UNIVERSITEIT
Organization address
address: GEERT GROOTEPLEIN NOORD 9 contact info |
NL (NIJMEGEN) | participant | 548˙293.00 |
| 12 |
ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM
Organization address
address: 's Gravendijkwal 230 contact info |
NL (ROTTERDAM) | participant | 417˙962.40 |
| 13 |
THE UNIVERSITY OF LIVERPOOL
Organization address
address: Brownlow Hill, Foundation Building 765 contact info |
UK (LIVERPOOL) | participant | 391˙679.00 |
| 14 |
GLAXOSMITHKLINE VACCINES SRL
Organization address
address: Via Fiorentina 1 contact info |
IT (SIENA) | participant | 298˙775.00 |
| 15 |
UNIVERSITY OF NEWCASTLE UPON TYNE
Organization address
address: Kensington Terrace 6 contact info |
UK (NEWCASTLE UPON TYNE) | participant | 80˙620.60 |
| 16 |
UNIVERSITAET BERN
Organization address
address: Hochschulstrasse 4 contact info |
CH (BERN) | participant | 0.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
Bacterial infection is the major cause of disability and death in children worldwide. We will use meningococcal disease (MD) as a model to understand genetic factors underlying susceptibility and severity of childhood bacterial infection which will then be applied to other childhood infections. We have established cohorts of patients with MD in Central and Southern Europe (CE,SE), UK and Africa as well as cohorts with other bacterial infections. We have established an inter-disciplinary team with expertise in Infectious Diseases, Immunogenetics, Bio-informatics, Microbiology, Public Health and Vaccinology including SME and industrial partners. We have already undertaken a genome wide study (GWAS) to identify genes causing susceptibility to meningococcal disease in a UK cohort. We identified complement factor H (fH) and fH-related (fHr) genes controlling MD susceptibility. This finding is fundamental to prevention as vaccines containing the MD fH receptor are undergoing trials. We will undertake GWAS on the CE, and SE MD cohorts, allowing meta analysis, and cross validation, and undertake GWAS on 2,500 Meningococcal Vaccine recipients. We will use next generation sequencing to identify the causal variants within the fH/fHr region and other regions implicated by pathway and severity analyses of the three MD GWAS and vaccine GWAS. We will match bacterial and host genetic variation and identify mechanisms of action of fH variants and other genes controlling susceptibility and severity using RNA expression, functional analyses and animal models. We will identify Mendelian defects and rare mutations as well as copy number variation and epi-genetic effects using next generation sequencing and RNA sequencing in “extreme phenotype” cohorts with MD , pneumococcal ,staphylococcal and salmonella disease. The study will identify mechanisms underlying susceptibility, provide new targets for treatment and prevention, and identify those at risk of disease or poor outcome.
Introduzione (Teaser)
Bacterial infection is the major cause of disability and death in children worldwide. Identifying the mechanisms underlying susceptibility provides new targets for treatment and prevention.